KIRKLAND, QC, Dec. 6, 2017 /CNW Telbec/ - Ortho Regenerative Technologies Inc. ("Ortho RTi" or the "Corporation"), an emerging Orthopaedic and Sports Medicine Technology company, today announced that a peer-reviewed article published in the current issue of Biomedical Materials has provided further validation that its "Ortho-R" hybrid implants release more growth factors and reside longer in the body than platelet rich plasma ("PRP") alone.
PRP is often used to treat different orthopedic conditions, however, the clinical benefits of using PRP alone remain uncertain. Ortho RTi's implants have been shown to improve meniscus, rotator cuff and cartilage repair in pre-clinical models. The purpose of study reported in the article was to investigate in vitro and in vivo mechanisms of action of the Ortho-R implants.
Quoting directly from the article, Ortho RTi's scaffold "physically coats platelets, blood cells and fibrin strands in [Ortho-R] hybrid clots, thus inhibiting platelet aggregation, which is required for clot retraction. Platelets are activated, granules secreted and higher levels of platelet-derived growth factor-AB and endothelial growth factor are released from [Ortho-R] hydrid clots compared to PRP clots in vitro. Finally, [Ortho-R] implants reside for at least 6 weeks post-implantation subcutaneously and induce cell recruitment and granulation tissue synthesis, confirming a longer residency and higher bioactivity compared to PRP in vivo."
"As evidence continues to mount that our proprietary biopolymer platform holds significant promise for improving the repair of three distinct joint tissues - the rotator cuff tendons, the meniscus and articular cartilage – our focus continues to be on advancing the technology's development and eventual product adoption," said the Corporation's Executive Chairman and CEO, Dr. Brent Norton.
An abstract of the article, entitled "Chitosan inhibits platelet-mediated clot retraction, increases platelet-derived growth factor release, and increases residence time and bioactivity of platelet-rich plasma in vivo," can be accessed on the internet at https://www.ncbi.nlm.nih.gov/pubmed/29125132.
Biomedical Materials is a peer-reviewed medical journal that publishes original research findings that contribute to our knowledge about the composition, properties, and performance of materials for tissue engineering and regenerative medicine.
About Ortho Regenerative Technologies Inc.
Ortho RTi is an emerging Orthopaedic and Sports Medicine technology company dedicated to the development of novel therapeutic tissue repair devices to dramatically improve the success rate of sports medicine surgeries. Ortho's proprietary biopolymer has been specifically designed to increase the healing rates of sports related injuries to ligaments, tendons and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Visit us on the internet at www.orthorti.com.
This news release may contain certain forward-looking statements regarding the Corporation's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Corporation disclaims any intention or obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.
SOURCE Ortho Regenerative Technologies Inc.
For further information: please contact: Stephen Kilmer, Investor & Media Relations, 647.872.4849, [email protected]